Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is focused on advancing innovative therapies and vaccines aimed at addressing significant unmet medical needs, particularly in retinal diseases through its Modifier Gene Therapy Platform. The company's ongoing Phase I/II study of OCU400 has shown promising efficacy and safety, which could substantially enhance investor confidence and market interest. Furthermore, attractive collaboration agreements and potential mergers and acquisitions may provide additional positive momentum for Ocugen's financial outlook.

Bears say

Ocugen Inc. has demonstrated limited efficacy in its treatment for geographic atrophy (GA) lesions, with the latest data showing a mere 20.2% slowing in lesion growth compared to untreated eyes, which raises concerns about the overall viability of its Modifier Gene Therapy Platform. The company faced challenges in securing necessary investment, citing poor market conditions and a tight compliance timeline for Nasdaq, which may hinder its ability to advance critical therapies. Overall, these factors contribute to a negative outlook on Ocugen's stock, as the company struggles to meet both clinical and financial expectations.

Ocugen, Inc. (OCGN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.